SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-19-022699
Filing Date
2019-11-13
Accepted
2019-11-13 17:00:04
Documents
8
Period of Report
2019-11-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K dffn20191113_8k.htm 8-K 35239
2 EXHIBIT 4.1 ex_164781.htm EX-4.1 107258
3 EXHIBIT 4.2 ex_164782.htm EX-4.2 106888
4 EXHIBIT 4.3 ex_164784.htm EX-4.3 104135
5 EXHIBIT 4.4 ex_164785.htm EX-4.4 112340
6 EXHIBIT 10.2 ex_164757.htm EX-10.2 210229
7 EXHIBIT 99.1 ex_164758.htm EX-99.1 13355
8 a1.jpg GRAPHIC 10894
  Complete submission text file 0001437749-19-022699.txt   700623
Mailing Address 2020 AVON COURT SUITE 4 CHARLOTTESVILLE VA 22902
Business Address 2020 AVON COURT SUITE 4 CHARLOTTESVILLE VA 22902 (434) 220-0718
Diffusion Pharmaceuticals Inc. (Filer) CIK: 0001053691 (see all company filings)

IRS No.: 300645032 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37942 | Film No.: 191214712
SIC: 2834 Pharmaceutical Preparations